All In Biotech

NDA 206353 · Bristol

Evotaz

Atazanavir Sulfate, Cobicistat · Oral · Cytochrome P450 3A Inhibitor

Last checked: Nov 19, 2026Latest source record: May 12, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Jan 29, 2015

Approved uses

3

Original approval plus efficacy supplements

Registered trials

216

68 Phase 3, 2 recruiting

FAERS reports

245

184 serious, 16 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 12, 2025.

EVOTAZ is a two-drug combination of atazanavir, a human immunodeficiency virus (HIV-1) protease inhibitor, and cobicistat, a CYP3A inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV‑1 infection in adults and pediatric patients weighing at least 35 kg. (1) Limitations of Use Use of EVOTAZ in treatment-experienced patients should be guided by the number of baseline primary protease inhibitor resistance substitutions. (1) 1.1 Indications EVOTAZ ® is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection in the following populations [see Dosage and Administration (2.2 , 2.3) ] : • Adult patients • Pediatric patients weighing at least 35 kg. 1.2 Limitations of Use Use of EVOTAZ in treatment-experienced patients should be guided by the number of baseline primary protease inhibitor resistance substitutions [see Clinical Pharmacology (12.4) ] .

Mechanism: EVOTAZ is a fixed-dose tablet consisting of the HIV-1 antiretroviral drug, atazanavir and the CYP3A inhibitor, cobicistat [see Clinical Pharmacology (12.4) ] .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • EVOTAZ · ATAZANAVIR SULFATE EQ 300MG BASE; COBICISTAT 150MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Atazanavir" as an intervention, any sponsor and status, largest first.

All 216 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pain43
  • emotional distress40
  • anxiety39
  • anhedonia36
  • osteoporosis25
  • chronic kidney disease21
  • foetal exposure during pregnancy21
  • bone density decreased18
  • osteopenia18
  • renal failure15
  • maternal exposure during pregnancy14
  • depression13

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201512
201621
201736
201824
201928
202034
202154
202212
202320
20241
20253

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Evotaz (Atazanavir Sulfate/Cobicistat)

2024 spending

$10.2M

Beneficiaries

690

6,152 claims

Per beneficiary

$14,752

$53.11 per unit

View as table
YearSpending
2020$19,564,434
2021$16,808,520
2022$14,758,381
2023$12,452,840
2024$10,179,004

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 350 on PubMed

Sponsor: Bristol Myers Squibb

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.